$SRDX (SurModics, Inc.)

$SRDX {{ '2015-11-20T14:28:40+0000' | timeago}} • Announcement

Medical device maker $SRDX said it acquired Creagh Medical, a maker of balloon catheters, for a total value of EUR30MM (approx. $32MM), with an upfront payment of EUR18MM, and up to EUR12MM based on future performance. $SRDX expects the deal to generate $3.5-4MM of revenue in FY16.

$EW {{ '2017-07-26T20:43:20+0000' | timeago}} • Announcement

For 3Q17, $EW projects underlying sales, adjusting for the impact of Germany stocking sales consumption, to be between $810-850MM, and adjusted earnings per share of $0.80 to $0.90.

$EW {{ '2017-07-26T20:42:56+0000' | timeago}} • Announcement

For FY17, $EW's full year sales estimate is now at the high end of its previous $3.2-3.4Bil guidance. Edwards Lifesciences Corp is also raising its estimate for FY17 adjusted earnings per share to $3.65-3.85, from $3.43-3.55.

$EW {{ '2017-07-26T20:40:21+0000' | timeago}} • Announcement

With strong demand for TAVR therapy resulted in total sales growth of 15% on an underlying basis, $EW's 2Q17 sales soared 11% to $841.8MM. Net income for the quarter jumped 47% to $186.1MM or $0.86 per diluted share. Adjusted earnings per share grew 42.1% to $1.08 while underlying sales rose 15% to about $864MM.

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$AMGN {{ '2017-07-26T19:57:57+0000' | timeago}} • Webcast

$AMGN has $39Bil cash on balance sheet, with no intention to consummate M&A transactions or repaying debt right now. The vast majority of cash is sitting offshore and the company is not considering to repatriate it under the current US tax system. The company said it will take a look at deploying the cash when some progress is made on tax reform.

$AMGN {{ '2017-07-26T19:34:18+0000' | timeago}} • Webcast

In 2Q17, $AMGN had a strong volume-driven growth from Prolia and other recently launched drugs including KYPROLIS and Repatha. Prolia sales increased 15% with an 18% volume growth YoY, with share gains in both the US and international markets.

$BIIB {{ '2017-07-26T13:59:55+0000' | timeago}} • Webcast

In multiple sclerosis, $BIIB's 2Q17 global TECFIDERA revenue growth was driven by volume growth, while patient growth in TECFIDERA was driven by its newly launched markets such as Italy, Poland & Japan. For FY17 ex-US, $BIIB expects SPINRAZA revenues to be modest, mainly from Germany and Japan. However, patient intake in the US is expected to grow.

$BIIB {{ '2017-07-26T13:46:38+0000' | timeago}} • Webcast

$BIIB's priority for capital deployment going forward is to invest in building its pipeline across its core growth areas like Alzheimer's, Parkinson's and neuromuscular disease and emerging areas like pain, ophthalmology and neuropsychiatry. $BIIB expects to have about $400MM available by 2019 for R&D and commercial value creation opportunities.

$BAX {{ '2017-07-26T12:58:04+0000' | timeago}} • Announcement

$BAX anticipates 2020 adjusted EPS of $3.25-3.40. $BAX also lifted its cash flow expectations for 2020 and now sees operating cash flow of about $2.65Bil. Capital expenditures are expected to total $650MM in 2020, resulting in free cash flow generation of about $2Bil, an increase of $250MM versus prior guidance.

$BAX {{ '2017-07-26T12:56:58+0000' | timeago}} • Announcement

As a result of ongoing business transformation efforts designed to accelerate performance, $BAX lifted its 2020 financial outlook. $BAX expects sales growth of 4% on a compounded annual basis from 2016 to 20202 and now sees adjusted operating margin in 2020 of about 20% as compared to previous guidance of 17-18%.

$BAX {{ '2017-07-26T12:55:25+0000' | timeago}} • Announcement

$BAX expects 3Q17 sales growth of about 4% on a reported basis, about 5% on a constant currency basis and about 6% operationally. The company expects earnings from continuing operations, before special items, of $0.58-0.60 per diluted share.

$BAX {{ '2017-07-26T12:54:23+0000' | timeago}} • Announcement

$BAX lifted 2017 EPS from continuing operations, before special items, guidance to $2.34-2.40 from $2.20-2.28. This guidance assumes the closure of the company's proposed acquisition of Claris Injectables, to be complete by the end of July 2017.

$BAX {{ '2017-07-26T12:52:56+0000' | timeago}} • Announcement

$BAX now expects 2017 sales growth of about 3% on a reported basis, about 4% on constant currency basis and about 5% operationally. Previously, the company had predicted sales growth of about 1-2% on a reported basis or 2-3% on a constant currency basis.

$BAX {{ '2017-07-26T12:46:39+0000' | timeago}} • Announcement

$BAX's renal sales totaled $968MM, comparable to the prior year on reported basis and up 3% on both a constant currency basis and operational basis. Growth was driven by increased sales for in-center hemodialysis (HD) products in the US, international acute renal care sales and global sales of peritoneal dialysis (PD) therapies.

$BAX {{ '2017-07-26T12:45:36+0000' | timeago}} • Announcement

$BAX's global sales for Hospital Products totaled $1.6Bil in 2Q17, rising 1% on reported, 2% on constant currency and 4% operationally. This was driven by continued strength in US fluid systems business, favorable demand for parenteral nutrition therapies and pre-mixed injectable, as well as for select anesthesia and critical care products.

$BAX {{ '2017-07-26T12:42:25+0000' | timeago}} • Announcement

$BAX reported a 78% dip in 2Q17 earnings due to last year's net realized gains from exchange of its retained shares of Baxalta and contribution to its U.S. pension fund. Net income dropped to $265MM or $0.48 per share from $1.21Bil or $2.19 per share last year. Net sales rose 1% to $2.61Bil. Adjusted EPS grew 37% to $0.63.

$AMGN {{ '2017-07-25T22:44:31+0000' | timeago}} • Announcement

$AMGN increased its 2017 earnings guidance to between $10.79 per share and $11.37 per share on GAAP basis, and between $12.15 per share and $12.65 per share on adjusted basis. Sales guidance was revised to a range of $22.5-23Bil.

$AMGN {{ '2017-07-25T22:43:15+0000' | timeago}} • Announcement

$AMGN reported a 15% YoY earnings growth in 2Q17 to $2.2Bil, or $2.91 per share, driven by a 4.9 percentage points increase in operating margin. Adjusted for one-time items, the company reported per-share earnings of $3.27. Revenue rose 2% to $5.8Bil.

Recent Transcripts

AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
MMM (3M Company)
Tuesday, July 25 2017 - 1:00pm
LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
ABC (AmerisourceBergen Corporation)
Thursday, May 4 2017 - 12:30pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
SRDX (SurModics, Inc.)
Thursday, April 27 2017 - 12:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
BAX (Baxter International Inc.)
Wednesday, April 26 2017 - 12:30pm
EW (Edwards Lifesciences Corp.)
Tuesday, April 25 2017 - 9:00pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
LLY (Eli Lilly and Company)
Tuesday, April 25 2017 - 1:00pm
MMM (3M Company)
Tuesday, April 25 2017 - 1:00pm

AlphaGraphics you may like